Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.63 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.63 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24881088 | 1.00 | DDB1 (0.63) | DDB1CRBNGPR119KDM4EMAPT | |
| SCHEMBL24319591 | 0.92 | DDB1 (0.58) | DDB1CRBNGPR119KDM4EMAPT | |
| SCHEMBL31630961 | 0.92 | DDB1 (0.63) | DDB1CRBNGPR119KDM4EMAPT | |
| SCHEMBL31443702 | 0.89 | DDB1 (0.64) | DDB1CRBNKDM4EMAPTTHRB | |
| SCHEMBL31443781 | 0.89 | DDB1 (0.63) | DDB1CRBNKDM4EMAPTTHRB | |
| SCHEMBL24880542 | 0.88 | DDB1 (0.55) | DDB1CRBNGPR119KDM4EMAPT | |
| SCHEMBL31444222 | 0.88 | DDB1 (0.60) | DDB1CRBNGPR119KDM4EMAPT | |
| SCHEMBL29197158 | 0.87 | DDB1 (0.59) | DDB1CRBNGPR119HRH3POLB | |
| SCHEMBL30631026 | 0.87 | DDB1 (0.66) | DDB1CRBNGPR119KDM4EMAPT | |
| SCHEMBL26633417 | 0.87 | DDB1 (0.66) | DDB1CRBNGPR119KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-4367113-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-116888108-B | Novel EGFR degradation agent | 上海齐鲁制药研究中心有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-116891502-A | EGFR degrading agent | 上海齐鲁制药研究中心有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-116888108-A | Novel EGFR degradation agent | 上海齐鲁制药研究中心有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022194269-A1 | NOVEL EGFR DEGRADATION AGENT | 上海齐鲁制药研究中心有限公司 | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | DDB1 3932/4885CRBN 207/4885GPR119 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.